Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 2/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29043387 | 0.98 | CYP3A4 (0.39) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL29639953 | 0.78 | PNMT (0.41) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL14637150 | 0.78 | HTR2C (0.40) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL30014903 | 0.78 | HTR2C (0.40) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL722943 | 0.78 | PNMT (0.50) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL29883454 | 0.78 | PNMT (0.50) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL13226202 | 0.78 | MB (0.40) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL694665 | 0.78 | PNMT (0.50) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL4407148 | 0.78 | PNMT (0.41) | CYP3A4POLBSMN1; SMN2CD44ASIC3 | |
| SCHEMBL29727983 | 0.78 | PNMT (0.50) | CYP3A4POLBSMN1; SMN2CD44ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116460017-B | Sheet metal part surface protective paint coating process | 上海槎南工贸发展有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-116460017-A | Sheet metal part surface protective paint coating process | 上海槎南工贸发展有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| CN-117801107-A | Benzazepine derivatives, conjugates containing same and application thereof | 上海迪诺医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023220541-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2023-11-16 | — | — | WO | disclosed |
| CN-116460017-B | Sheet metal part surface protective paint coating process | 上海槎南工贸发展有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116460017-A | Sheet metal part surface protective paint coating process | 上海槎南工贸发展有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | disclosed |
| WO-2020056008-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | SILVERBACK THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019118884-A1 | ANTIBODY CONSTRUCT-DRUG CONJUGATE FOR THE TREATMENT OF HEPATITIS | SILVERBACK THERAPEUTICS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2008149163-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | CYP3A4 105/4885POLB 2208/4885SMN1; SMN2 4520/4885 |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | CYP3A4 2881/4885POLB 1999/4885SMN1; SMN2 3906/4885 |
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | CYP3A4 3775/4885POLB 2503/4885SMN1; SMN2 3998/4885 |
| US-20220289753-A1 | SHP2 INHIBITORS | PTPN1, PTPN2, PTPN7 | CYP3A4 4565/4885POLB 4199/4885SMN1; SMN2 4332/4885 |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | CYP3A4 635/4885POLB 2781/4885SMN1; SMN2 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.